Optimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableOptimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Alexandria May, PharmD, BCPS
Michael Czarnecki, MD
How to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableHow to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Brian P. McDonough, MD, FAAFP
Brooks Kuhn, MD, MAS
A Phenotype-Driven Approach to Alpha-1 Antitrypsin Deficiency Care
Clinician's RoundtableA Phenotype-Driven Approach to Alpha-1 Antitrypsin Deficiency Care
Brian P. McDonough, MD, FAAFP
MeiLan Han, MD, MS
Predicting PPD Risk: A Biomarker-Based Approach
Advances in Women's HealthPredicting PPD Risk: A Biomarker-Based Approach
Jennifer L. Payne, MD
Conference Coverage at ICCBH 2026: A New Frontier in Achondroplasia—Clinical Insights From the PROPEL 3 Trial of Oral Infigratinib in Children
EndocrinologyConference Coverage at ICCBH 2026: A New Frontier in Achondroplasia—Clinical Insights From the PROPEL 3 Trial of Oral Infigratinib in Children
Ravi Savarirayan, MBBS, MD
How Genetic Testing Guides Personalized mBC Care
On the Frontlines of Metastatic Breast CancerHow Genetic Testing Guides Personalized mBC Care
Alexandria May, PharmD, BCPS
Marie Wood, MD
- advertisement
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
CME/CEFuture-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
Marc A. Riedl, MD, MS
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
MinuteCE®Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
CASR and ADH1: Integrating Biology and Genetic Screening
MinuteCE®CASR and ADH1: Integrating Biology and Genetic Screening
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Therapeutic Options for ADH1 and Hypoparathyroidism
MinuteCE®Therapeutic Options for ADH1 and Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Emerging Therapeutics in ADH1: Progress in Precision Medicine
MinuteCE®Emerging Therapeutics in ADH1: Progress in Precision Medicine
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
- advertisement
- 07/02/2026
- 06/29/2026
- 05/25/2026
- 05/20/2026
- 05/14/2026
- 05/01/2026